军事知识服务平台
喷昔洛韦联合溴夫定治疗重度疼痛带状疱疹的疗效分析
Efficacy and safety of penciclovir combined with brivudine for herpes zoster with severe pain
摘要 目的:探讨喷昔洛韦联合溴夫定治疗重度疼痛带状疱疹的有效性及安全性。方法:回顾性收集2023年1月至2025年10月天津医科大学总医院皮肤性病科病房收治的129例重度疼痛带状疱疹患者为研究对象。按治疗方案分为联合用药组(喷昔洛韦+溴夫定, n=58)和喷昔洛韦组( n=71)。比较两组患者的皮损止疱时间、结痂时间,治疗第3、第7天及结束当天疼痛数字评定量表(NRS)评分、镇痛药物用量,带状疱疹后神经痛(PHN)及不良反应发生率。采用SPSS 23.0软件对数据进行分析。 结果:联合用药组的止疱时间[(1.91±0.86)d]和结痂时间[(4.81±0.91)d]均短于喷昔洛韦组[(2.52±0.58)d和(6.23±1.71)d],差异均有统计学意义( t=7.682和16.944, P值均<0.001)。治疗后第3、7天及治疗结束当天,联合用药组NRS评分均低于喷昔洛韦组( t=10.867、8.263和5.887, P值均<0.001)。联合用药组曲马多用量在治疗后第3、7天及治疗结束当天均低于喷昔洛韦组( t=46.249、25.032、15.589, P值均<0.001);普瑞巴林用量在治疗后第7天及治疗结束当天亦低于喷昔洛韦组( t=51.357和34.589, P值均<0.001)。联合用药组的PHN发生率为5.17%(3/58),喷昔洛韦组为12.68%(9/71),差异无统计学意义( P=0.223)。两组的不良反应发生率差异无统计学意义(18.96%比16.90%, χ2=0.093, P=0.761)。 结论:喷昔洛韦联合溴夫定治疗重度疼痛带状疱疹有助于更快控制皮损、缓解疼痛,并减少镇痛药物的使用,且显示良好的安全性。
Abstract:
Objective:To evaluate the efficacy and safety of penciclovir combined with brivudine for herpes zoster with severe pain.Methods:A total of 129 inpatients with herpes zoster presenting severe pain admitted to the Department of Dermatovenereology,Tianjin Medical University General Hospital from January 2023 to October 2025 were retrospectively enrolled. The patients were divided into combination group(penciclovir + brivudine, n=58)and penciclovir group( n=71)according to the treatment regimen. The time to cessation of new blisters,time to crusting,numerical rating scale(NRS)scores on day 3,day 7 and at the end of treatment,analgesic consumption,incidence of postherpetic neuralgia(PHN),and adverse reactions were compared between the two groups. Statistical analysis was performed using SPSS 23.0. Results:The combination group had significantly shorter times to cessation of new blisters[(1.91±0.86)d]and crusting[(4.81±0.91)d]compared with the penciclovir group[(2.52±0.58)d and(6.23±1.71)d,respectively]( t=7.682 and 16.944,both P<0.001). NRS scores were significantly lower in the combination group than those in the penciclovir group on days 3,7,and at end of treatment( t=10.867,8.263 and 5.887,all P < 0.001). Tramadol use was significantly lower in the combination group on days 3,7,and at end of treatment( t=46.249,25.032,15.589,all P<0.001). Pregabalin use was also significantly lower in the combination group on day 7 and at the end of treatment( t=51.357 and 34.589,both P<0.001). The PHN incidence was 5.17%(3/58)in the combination group versus 12.68%(9/71)in the penciclovir group,but the difference was not statistically significant( P=0.223). Adverse reaction rates were similar between groups(18.96% vs. 16.90%, χ2=0.093, P=0.761). Conclusion:Penciclovir combined with brivudine for herpes zoster with severe pain may accelerate skin lesion resolution and pain relief,reduce analgesic requirements,and has a favorable safety profile.